Details

Autor(en) / Beteiligte

• Funayama, Akira, MD
• Shishido, Tetsuro, MD, PhD
• Netsu, Shunsuke, MD
• Ishino, Mitsunori, MD
• Sasaki, Toshiki, MD, PhD
• Katoh, Shigehiko, MD, PhD
• Takahashi, Hiroki, MD, PhD
• Arimoto, Takanori, MD, PhD
• Miyamoto, Takuya, MD, PhD
• Nitobe, Joji, MD, PhD
• Watanabe, Tetsu, MD, PhD
• Kubota, Isao, MD, PhD

Titel

Serum Pregnancy-Associated Plasma Protein A in Patients With Heart Failure

Ist Teil von

• Journal of cardiac failure, 2011-10, Vol.17 (10), p.819-826

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2011

Quelle

MEDLINE

Beschreibungen/Notizen

• Abstract Background Pregnancy-associated plasma protein A (PAPP-A) proteolyzes insulin-like growth factor (IGF)–binding proteins and thus increases IGF-1 bioactivity. PAPP-A has been reported to be involved in various pathophysiologic abnormalities; however, the clinical significance of PAPP-A has not been examined in cases of heart failure (HF). We hypothesized that PAPP-A levels might be correlated with the severity of HF. Methods and Results PAPP-A and B-type natriuretic peptide (BNP) levels were measured in 262 subjects (182 HF patients and 80 control subjects). PAPP-A levels were higher in patients with HF than in control subjects and increased with advancing New York Heart Association functional class. There were 53 cardiac events during a mean follow-up period of 796 days. PAPP-A levels were higher in patients with cardiac events than in event-free patients. Patients were divided into 3 groups on the basis of their PAPP-A and BNP levels. Kaplan-Meier analysis demonstrated that the group with both high BNP with high PAPP-A had a significantly higher cardiac event rate than other groups. Conclusions Serum PAPP-A levels were related to the severity of HF and associated with a high risk for adverse cardiac events in HF patients, suggesting that PAPP-A might be involved in the pathogenesis of HF.